LoJaimiess NDC 70700-124

NDC codes

FDA NDC Directory

Product NDC (as listed)70700-124Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70700-0124Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70700-124-87	70700012487	1 BLISTER PACK in 1 CARTON (70700-124-87) / 1 KIT in 1 BLISTER PACKMarketed from Feb 11, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): LoJaimiess
Generic name (nonproprietary): levonorgestrel/ethinyl estradiol and ethinyl estradiol
Dosage form: Kit
Labeler: Xiromed, LLC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205131
Marketing start: Feb 11, 2019
Listing expires: Dec 31, 2027
Identifiers: Product ID 70700-124_c9d773e9-d3c5-60f9-fcfb-a107b891d688SPL ID c9d773e9-d3c5-60f9-fcfb-a107b891d688SPL set ID 5f0b397c-256a-0163-35c7-e9401705b439RxCUI 242297, 248310, 810096, 2117770

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470700012487 followed by a unit qualifier and the quantity

Package 70700-0124-87. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 12, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

LoJaimiess is indicated for use by females of reproductive potential to prevent pregnancy. LoJaimiess is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)